Press Release Headlines

Kibow Biotech Marks World Kidney Day with Introduction of Renadyl™ Product to India Market

Product launch to coincide with 9th Nutra India Summit in Bangalore

NEWTOWN SQUARE, Pa., March 13, 2014 /PRNewswire/ — Kibow Biotech is pleased to announce that it will mark World Kidney Day (March 13, with the launch of Renadyl™, its patented, clinically validated probiotic dietary supplement for kidney health, in India. This milestone event will coincide with Kibow's participation as a NuFFoods probiotics sponsor at the 9th Nutra India Summit, March 12-14, 2014 in Bangalore, India (

Photo –

Photo –

The product launch will take place on March 13th, during a dinner gala at Le Meridien Hotel in Bangalore. This event represents a major turning point for Kibow Biotech, whose primary goal is to help improve the quality of life for kidney disease patients worldwide by complementing their standard-of-care therapy with probiotic dietary supplementation. Of particular interest to Kibow Biotech are the patients in underdeveloped and developing countries, where access to the commonly accepted treatment modalities of dialysis and transplantation, both highly invasive and costly, is severely limited.

Throughout 16 years of continuous R&D, Kibow Biotech's team has been privileged to provide support to kidney disease patients worldwide in their struggle with chronic kidney failure. Kibow remains passionate about patient health and continues to focus its research efforts on developing new dietary supplement formulations that can provide additional health benefits, specifically, an improved quality of life for consumers worldwide.

About Kibow Biotech: Founded Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

For further information, contact:

Natarajan Ranganathan, PhD
Managing Director
1 (610) 353-5130